Zofenopril
Antihypertensive drug of the ACE inhibitor class
- C09AA15 (WHO)
- (2S,4S)-1-[(2S)-3-benzoylsulfanyl-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid
- 81872-10-8
Y
- 92400
- 6462
- DB13166
N
- 83422
N
- 290ZY759PI
- D08688
Y
- CHEBI:78539
N
- ChEMBL331378
N
- DTXSID0046640
- Interactive image
- O=C(N2[C@H](C(=O)O)C[C@H](Sc1ccccc1)C2)[C@H](C)CSC(=O)c3ccccc3
InChI
- InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1
N
- Key:IAIDUHCBNLFXEF-MNEFBYGVSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Zofenopril (INN) is a medication that protects the heart and helps reduce high blood pressure. It is an angiotensin-converting enzyme (ACE) inhibitor.[1]
In small studies, zofenopril appeared significantly more effective in reducing hypertension than two older antihypertensive drugs, atenolol and enalapril, and was associated with fewer adverse effects.[2][3]
Zofenopril is a prodrug with zofenoprilat as the active metabolite.[4]
It was patented in 1978 and approved for medical use in 2000.[5]
References
- ^ Ambrosioni E (2007). "Defining the role of zofenopril in the management of hypertension and ischemic heart disorders". American Journal of Cardiovascular Drugs. 7 (1): 17–24. doi:10.2165/00129784-200707010-00002. PMID 17355163. S2CID 41320204.
- ^ Nilsson P (October 2007). "Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension". Blood Pressure. Supplement. 2: 25–30. doi:10.1080/08038020701561745. PMID 18046976. S2CID 22145457.
- ^ Mallion JM (October 2007). "An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension". Blood Pressure. Supplement. 2: 13–18. doi:10.1080/08038020701561703. PMID 18046974. S2CID 27469549.
- ^ Subissi A, Evangelista S, Giachetti A (1999). "Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties". Cardiovascular Drug Reviews. 17 (2): 115–133. doi:10.1111/j.1527-3466.1999.tb00008.x.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 978-3-527-60749-5.
- v
- t
- e
("-pril")
- Sulfhydryl-containing: Captopril
- Rentiapril
- Zofenopril (+nebivolol)
- Dicarboxylate-containing: Enalapril# (+lercanidipine, +nitrendipine)
- Benazepril (+amlodipine, +pimobendan)
- Cilazapril
- Delapril (+manidipine)
- Imidapril
- Lisinopril (+amlodipine, +HCT)
- Moexipril
- Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide)
- Quinapril (+HCT)
- Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine)
- Spirapril
- Temocapril
- Trandolapril (+verapamil)
- Phosphonate-containing: Ceronapril
- Fosinopril (+HCT)
- Other/ungrouped: Alacepril
("-sartan")
- Azilsartan
- Candesartan (+amlodipine, +amlodipine and HCT)
- Eprosartan
- Fimasartan
- Irbesartan (+amlodipine, +amlodipine and HCT, +HCT)
- Losartan (+amlodipine, +HCT)
- Olmesartan (+amlodipine, +amlodipine and HCT, +HCT)
- Tasosartan§
- Telmisartan (+amlodipine, +amlodipine and HCT, +HCT)
- Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
("-kiren")
- Gemopatrilat
- Ilepatril
- Omapatrilat
- Sampatrilat
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e